Item 7.01. Regulation FD Disclosure.

On January 27, 2020, Meridian Bioscience, Inc. (the "Company") issued a press release announcing that certain diagnostic companies and laboratories located in China have engaged the Company to use the Company's Lyo-Ready 1-Step RT-qPCR Mix to develop screening assays for the detection of the coronavirus, currently named 2019-nCoV (the "Coronavirus"), which has and is continuing to spread throughout China and other parts of the world. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated by reference herein.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this are "forward-looking" statements made within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "anticipate," "believe," "ensure," "expect," "if," "intend," "estimate," "probable," "project," "forecasts," "predict," "outlook," "aim," "will," "could," "should," "would," "potential," "may," "might," "anticipate," "likely," "plan," "positioned," "strategy," and similar expressions, and the negative thereof, are intended to identify forward-looking statements.

All forward-looking information is subject to numerous risks and uncertainties, many of which are beyond the control of the Company, that could cause actual results to differ materially from the results expressed or implied by the statements. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this communication may become outdated over time. The Company does not assume any responsibility for updating any forward-looking statements. Additional information concerning these and other factors can be found in the Company's filings with the SEC and available through the SEC's Electronic Data Gathering and Analysis Retrieval system at www.sec.gov, including the Company's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The foregoing list of important factors is not exclusive. The Company assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, except as may be required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.




Item 8.01.  Other Events.

As described in Item 7.01 of this Form 8-K, on January 27, 2020, the Company issued a press release announcing that certain diagnostic companies and laboratories located in China have engaged the Company to use the Company's Lyo-Ready 1-Step RT-qPCR Mix to develop screening assays for the detection of the Coronavirus.

The information in each of Item 7.01 and Item 8.01 of this Form 8-K and in the press release attached as Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in each of Item 7.01 and Item 8.01 of this Form 8-K and each of Exhibit 99.1 shall not be incorporated by reference in any filing (whether made before or after the date hereof) or any other document under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing or document.

© Edgar Online, source Glimpses